Cantargia AB (CHIX:CANTAS) Marketable Securities: kr12.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:CANTAS Cantargia AB CHIX:CANTAS
32 GF Score
Price kr4.17
! 2 Warning Signs
View Full Analysis

What is Cantargia AB Marketable Securities?

Cantargia AB CHIX:CANTAS 32 Marketable Securities is kr12.0 Mil as of Mar. 2026. GuruFocus rates CHIX:CANTAS with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Cantargia AB's Marketable Securities for the quarter that ended in Mar. 2026 was kr12.0 Mil.

Cantargia AB's annual Marketable Securities declined from Dec. 2023 (kr55.0 Mil) to Dec. 2024 (kr0.0 Mil) but then stayed the same from Dec. 2024 (kr0.0 Mil) to Dec. 2025 (kr0.0 Mil).

Cantargia AB  (CHIX:CANTAs) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Cantargia AB Marketable Securities Related Terms

Cantargia AB Marketable Securities Historical Data

* Premium members only.

The historical data trend for Cantargia AB's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantargia AB Marketable Securities Chart

Cantargia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 312.06 237.10 55.00 0.00 0.00

Cantargia AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 12.00
CHIX:CANTAS
32GF Score
Cantargia AB CHIX:CANTAS
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cantargia AB Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of kr12.0 Mil mean?
Cantargia AB (CHIX:CANTAS) has a Marketable Securities of kr12.0 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Cantargia AB and its competitors.
Is Cantargia AB's Marketable Securities too high?
Cantargia AB's current Marketable Securities is kr12.0 Mil. Overall, Cantargia AB has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Cantargia AB's Marketable Securities compare to VRTX and REGN?
Cantargia AB's Marketable Securities of kr12.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Cantargia AB and its competitors. Cantargia AB's current Marketable Securities is kr12.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantargia AB stock overvalued right now?
Cantargia AB (CHIX:CANTAS) has a current Marketable Securities of kr12.0 Mil. The current Marketable Securities is kr12.0 Mil. Cantargia AB's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Cantargia AB (CHIX:CANTAS), the current Marketable Securities is kr12.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantargia AB Business Description

Other Exchanges CANTA:Sweden7V3:Germany
Address Scheelevagen 27, Lund, SWE, 223 63
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
32GF Score

Get the complete analysis for CHIX:CANTAS

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr4.17
Price